Small-molecule inhibitors, referred to as Smac (second mitochondrial-derived activator of caspases) mimetics (SM), have been developed to target IAPs and are currently undergoing clinical trials for cancer treatment34,35. The gene discussed is DIABLO; the disease is cancer.